Janux Therapeutics, Inc.
JANX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001817713
No open-market purchases or sales by Janux Therapeutics, Inc. insiders were filed in the last 90 days; 197 institutions reported holding it in 13F filings for Q2 2026, worth $933.4M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 13, 2026
- $695.7M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +9 vs. previous quarter
- 197
- 13F valueReported value at the end of Q2 2026
- $933.4M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $10.0M
- −5.6% year over year
- Net income, FY2025
- -$113.6M
- No comparable prior period
- Free cash flow, FY2025
- -$83.3M
- No comparable prior period
- Revenue, Q3 FY2026
- $9.29M
- −7.1% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $113.6M (1136.3% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 5.33M
- Shares sold short
- Change
- +2.77K
- +0.1% vs. previous
- Days to cover
- 7.98
- At average daily volume
Superinvestors holding JANX, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding JANX at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Janux Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 4, 2026 (view filing) | Jun 2 | 2 days | Doyle Janeen NoelChief Corp. & Bus. Dev. Ofcr | SSale | −4.06K | $14.03 | −$56.9K | −5.1%75.9K after | |
| May 13, 2026 (view filing) | May 11 | 2 days | Dobek MariaVice President, Accounting | SSale | −2.04K | $14.17 | −$28.9K | −5.9%32.3K after | |
| Jan 2, 2026 (view filing) | Jan 2 | Same day | McIver ZachariahChief Medical Officer | SSale | −2.71K | $13.73 | −$37.3K | −10.4%23.3K after | |
| Jan 2, 2026 (view filing) | Jan 2 | Same day | Dobek MariaVice President, Accounting | SSale | −1.46K | $13.73 | −$20.1K | −8.7%15.4K after | |
| Jan 2, 2026 (view filing) | Jan 2 | Same day | DiRaimondo ThomasChief Scientific Officer | SSale | −2.50K | $13.73 | −$34.4K | −2.0%124.4K after | |
| Jan 2, 2026 (view filing) | Jan 2 | Same day | Winter Charles M.Chief Technical Officer | SSale | −2.40K | $13.73 | −$33.0K | −3.0%77.7K after | |
| Jan 2, 2026 (view filing) | Jan 2 | Same day | Meyer Andrew HollmanChief Business Officer | SSale | −1.88K | $13.73 | −$25.8K | −2.2%83.1K after | |
| Jan 2, 2026 (view filing) | Jan 2 | Same day | Campbell David AlanPresident and CEO | SSale | −8.07K | $13.73 | −$110.8K | −2.8%285.0K after | |
| Dec 3, 2025 (view filing) | Dec 1 | 2 days | Meyer Andrew HollmanChief Business Officer | SSale | −3.33K | $32.98 | −$109.9K | −3.8%85.0K after | 2 lots10b5-1 |
| Nov 14, 2025 (view filing) | Nov 14 | Same day | Meyer Andrew HollmanChief Business Officer | SSale | −3.33K | $30.00 | −$100.0K | −3.8%85.0K after | 10b5-1 |
Top 10 13F holders, Q2 2026
See all 197 holdersThe largest institutional positions in Janux Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 11,189,693 | $171.9M | 1.49% | 00.0% | Unchanged |
| BlackRock, Inc. | 6,134,667 | $94.2M | 0.00% | +701,434+12.9% | Added |
| Prosight Management, LP | 3,804,481 | $58.4M | 10.07% | +254,481+7.2% | Added |
| State Street Corp | 3,004,899 | $46.2M | 0.00% | +540,882+22.0% | Added |
| FMR LLC | 2,412,825 | $37.1M | 0.00% | −122,899−4.8% | Reduced |
| Federated Hermes, Inc. | 2,352,927 | $36.1M | 0.05% | +2,298,727+4,241.2% | Added |
| Point72 Asset Management, L.P. | 1,993,837 | $30.6M | 0.05% | +837,697+72.5% | Added |
| Vanguard Capital Management LLC | 1,857,351 | $28.5M | 0.00% | +45,986+2.5% | Added |
| TCG Crossover Management, LLC | 1,789,617 | $27.5M | 0.66% | 00.0% | Unchanged |
| Alyeska Investment Group, L.P. | 1,647,140 | $25.3M | 0.07% | +46,051+2.9% | Added |
Holders of 5% or more of JANX
See all 3 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Janux Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 13D/A | 19.90%12.0M shares | – | Jun 16, 20215 filings | Mar 10, 2025 | SEC |
| BlackRock, Inc. | 13G/A | 6.70%4.10M shares | +1.00 ppfrom 5.70% | Jul 17, 20252 filings | Jul 28, 2026 | SEC |
| Prosight Management, LP | 13G | 5.30%3.16M shares | New | Feb 6, 20261 filing | Feb 6, 2026 | SEC |